Gene · 10481
Papers1,917
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 1,917
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors. | Endocr Pathol | 2023 | 37552455 | PubTator, text mining | PubMed |
| GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression. | J Exp Clin Cancer Res | 2023 | 37550764 | PubTator, text mining | PubMed |
| Cell-free DNA in the management of prostate cancer: Current status and future prospective. | Asian J Urol | 2023 | 37538150 | PubTator, text mining | PubMed |
| Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer. | JCO Precis Oncol | 2023 | 37535880 | PubTator, text mining | PubMed |
| Survivin prevents the polycomb repressor complex 2 from methylating histone 3 lysine 27. | iScience | 2023 | 37534134 | PubTator, text mining | PubMed |
| "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?" | Breast Cancer (Dove Med Press) | 2023 | 37533589 | PubTator, text mining | PubMed |
| Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing. | Int J Mol Sci | 2023 | 37511593 | PubTator, text mining | PubMed |
| DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. | Int J Mol Sci | 2023 | 37511177 | PubTator, text mining | PubMed |
| Biomarkers in Breast Cancer: An Old Story with a New End. | Genes (Basel) | 2023 | 37510269 | PubTator, text mining | PubMed |
| Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis. | Cancers (Basel) | 2023 | 37509234 | PubTator, text mining | PubMed |
| GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer. | BMC Womens Health | 2023 | 37507701 | PubTator, text mining | PubMed |
| Super-enhancers complexes zoom in transcription in cancer. | J Exp Clin Cancer Res | 2023 | 37501079 | PubTator, text mining | PubMed |
| In Vitro Antiproliferative Effects and Phytochemical Characterization of Carissa edulis ((Forssk) Vahl) and Pappea capensis (Eckyl and Zeyh) Extracts. | J Evid Based Integr Med | 2023 | 37489007 | PubTator, text mining | PubMed |
| A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer. | Mol Cancer Ther | 2023 | 37486978 | PubTator, text mining | PubMed |
| TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma. | PLoS One | 2023 | 37478120 | PubTator, text mining | PubMed |
| Unique Spectrum of Activating BRAF Alterations in Prostate Cancer. | Clin Cancer Res | 2023 | 37477913 | PubTator, text mining | PubMed |
| Novel insights into the nervous system affected by prolonged hyperglycemia. | J Mol Med (Berl) | 2023 | 37462767 | PubTator, text mining | PubMed |
| Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC. | Front Oncol | 2023 | 37456235 | PubTator, text mining | PubMed |
| Role of N6-methyladenosine RNA modification in gastric cancer. | Cell Death Discov | 2023 | 37443100 | PubTator, text mining | PubMed |
| Stability selection enhances feature selection and enables accurate prediction of gestational age using only five DNA methylation sites. | Clin Epigenetics | 2023 | 37443060 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10481/papers?page=12